by lythamcorp | Nov 12, 2024 | Cadrenal Therapeutics, Cadrenal Therapeutics News, Healthcare
Leading heart failure specialist features tecarfarin data and Cadrenal’s proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla., Nov. 12, 2024 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage...
by lythamcorp | Nov 12, 2024 | Industrials, SenesTech, SenesTech News
Significantly Expanding Market Reach PHOENIX, Nov. 12, 2024 — SenesTech, Inc. (Nasdaq: SNES; “SenesTech” or the “Company”), a leader in fertility control solutions for managing animal pest populations, is excited to announce a significant...
by lythamcorp | Nov 12, 2024 | Mogo, MOGO News, Technology
VANCOUVER, British Columbia – Carta Worldwide (“Carta”), a global digital payment solutions business owned and operated independently by Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO), today announced that it processed just under $3.0 billion of payment volume...
by lythamcorp | Nov 12, 2024 | Healthcare, NeurAxis News
Conference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation...
by lythamcorp | Nov 12, 2024 | Reviva Pharma News
– 108 patients have completed 1-year of treatment – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December...